Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Sep 6:12:e91831.
doi: 10.7554/eLife.91831.

Protecting the heart

Joshua M Inglis  1   2 , Arduino A Mangoni  1
Affiliations
Comment

Protecting the heart

Joshua M Inglis et al. Elife. .

Abstract

Blocking a protein known as EPAC1 may prevent the development of heart-related side effects caused by a chemotherapy drug.

Keywords: EPAC1; cancer biology; cancer survivorship; cardiotoxicity; cell biology; doxorubicin; human; mouse; rat.

PubMed Disclaimer

Conflict of interest statement

JI, AM No competing interests declared

Figures

Figure 1.
Figure 1.. Loss of EPAC1 reduces heart damage in mice receiving doxorubicin.
Table showing the prevention of doxorubicin-induced cardiomyopathy in wild-type and EPAC1 knockout mice (i.e., mice without the EPAC1 gene). Increased EPAC1 expression was seen in wild-type mice receiving doxorubicin who also developed cardiomyopathy.
See this image and copyright information in PMC

Comment on

  • EPAC1 inhibition protects the heart from doxorubicin-induced toxicity.
    Mazevet M, Belhadef A, Ribeiro M, Dayde D, Llach A, Laudette M, Belleville T, Mateo P, Gressette M, Lefebvre F, Chen J, Bachelot-Loza C, Rucker-Martin C, Lezoualch F, Crozatier B, Benitah JP, Vozenin MC, Fischmeister R, Gomez AM, Lemaire C, Morel E. Mazevet M, et al. Elife. 2023 Aug 8;12:e83831. doi: 10.7554/eLife.83831. Elife. 2023. PMID: 37551870 Free PMC article.

References

    1. Emery J, Butow P, Lai-Kwon J, Nekhlyudov L, Rynderman M, Jefford M. Management of common clinical problems experienced by survivors of cancer. The Lancet. 2022;399:1537–1550. doi: 10.1016/S0140-6736(22)00242-2. - DOI - PubMed
    1. Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, Sabbah A, Woronoff-Lemsi MC, Cahn JY. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Annals of Oncology. 2003;14:277–281. doi: 10.1093/annonc/mdg070. - DOI - PubMed
    1. Mazevet M, Belhadef A, Ribeiro M, Dayde D, Llach A, Laudette M, Belleville T, Mateo P, Gressette M, Lefebvre F, Chen J, Bachelot-Loza C, Rucker-Martin C, Lezoualch F, Crozatier B, Benitah J-P, Vozenin M-C, Fischmeister R, Gomez A-M, Lemaire C, Morel E. EPAC1 inhibition protects the heart from doxorubicin-induced toxicity. eLife. 2023;12:e83831. doi: 10.7554/eLife.83831. - DOI - PMC - PubMed
    1. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, Childhood Cancer Survivor Study Chronic health conditions in adult survivors of childhood cancer. The New England Journal of Medicine. 2006;355:1572–1582. doi: 10.1056/NEJMsa060185. - DOI - PubMed
    1. Romond EH, Jeong J-H, Rastogi P, Swain SM, Geyer CE, Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology. 2012;30:3792–3799. doi: 10.1200/JCO.2011.40.0010. - DOI - PMC - PubMed